Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.

ABSTRACT: Recurrent glioblastoma (GBM) has a very low 6-month progression free survival (PFS) with currently available treatments. Combination chemotherapy to target multiple cell signaling pathways is currently being investigated in order to improve prognosis for recurrent disease. The purpose of this phase I study was to determine the maximum tolerated dose (MTD) for the combination of tipifarnib and sorafenib for the treatment of recurrent GBM. Patients with pathologically proven WHO grade IV GBM and radiographically proven tumor recurrence were eligible for this study. Treatments included sorafenib at twice daily and escalating dosages of tipifarnib. Dose-limiting toxicity (DLT) was determined over the first 28-days of treatments, and the MTD was determined in a 3 + 3 study design. We enrolled 2

SUBMITTER: Nghiemphu PL 

PROVIDER: S-EPMC5756101 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature